Clinical trials: Bronchial Asthma
Bronchial Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.
- Trial name
- NCT06154304
- Testing
- Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Cipla Ltd.
Bronchial Asthma
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
- Trial name
- NCT07054034
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
Bronchial Asthma, Airway Disease
FeNO Detection in Asthma Diagnosis: A New Technology Approach
The detection of exhaled nitric oxide (FeNO) represents a non-invasive, safe, and rapid approach for assessing endogenous nitric oxide (NO) levels within the airway.
- Trial name
- NCT06852911
- Testing
- Chemiluminescent FeNO Analyzer, Electrochemical FeNO Analyzer
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Novlead Inc.
Bronchial Asthma
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma
- Trial name
- NCT06637254
- Testing
- HSK31858
- Where
- China
- Volunteers
- 219 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Rhinitis, Allergic, Seasonal, Asthma, Bronchial
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing…
- Trial name
- NCT00092885
- Testing
- MK0476, montelukast sodium
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Asthma, Bronchial
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.
- Trial name
- NCT00489346
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year
- Volunteers
- 994 people
- Sponsor
- Organon and Co
Asthma, Bronchial
Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma.
- Trial name
- NCT00092092
- Testing
- Montelukast chewable tablets, Budesonide inhaler
- Volunteers
- 71 people
- Sponsor
- Organon and Co
Asthma, Bronchial, Rhinitis, Allergic, Perennial
Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)
The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.
- Trial name
- NCT00092105
- Testing
- MK0476, montelukast sodium
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Allergic Asthma
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
This is a phase I an open-label randomized comparative study in parallel groups of pharmacokinetics, pharmacodynamics, immunogenicity, and safety of Genolair in two dosage forms (solution for subcutaneous administration and…
- Trial name
- NCT06494345
- Testing
- Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg
- Where
- Russia
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Bronchial Asthma
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.
Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.
- Trial name
- NCT02455687
- Testing
- Hi-dose iv MgSO4, Nebulized budesonide, Std-dose iv MgSO4
- Where
- Qatar
- Volunteers
- 240 people
- Sponsor
- Hamad Medical Corporation
Bronchial Asthma
To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark…
- Trial name
- NCT05363202
- Testing
- Fluticasone propionate Inhalation Aerosol 44 mcg, FLOVENT HFA 44 mcg
- Where
- 11 sites in India
- Volunteers
- 790 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Bronchial Asthma
Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg
- Trial name
- NCT05292976
- Testing
- Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference)
- Where
- United States
- Sponsor
- Aurobindo Pharma Ltd
Asthma, Bronchial Diseases
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive
- Trial name
- CASCADE (NCT03688074)
- Testing
- Tezepelumab
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Asthma, Bronchial
A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)
A study to determine the effects of montelukast (MK-0476) on pediatric participants with chronic asthma compared with fluticasone.
- Trial name
- NCT00540839
- Testing
- Montelukast sodium, Fluticasone propionate
- Sponsor
- Organon and Co
Asthma
Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the…
- Trial name
- NCT00232999
- Testing
- Nebulized IVX-0142
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe…
- Trial name
- ANDHI (NCT03170271)
- Testing
- Benralizumab (Medi-563)
- Where
- 213 sites in United States, Austria and 12 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Asthma
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over…
- Trial name
- NCT03629249
- Testing
- QAW039 150 mg once daily, QAW039 450 mg once daily
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 604 people
- Sponsor
- Novartis Pharmaceuticals
Nasal Polyps
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years)…
- Trial name
- THUNDER (NCT03681093)
- Testing
- Fevipiprant 150 mg, Fevipiprant 450 mg
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals